
CAR T-cell therapy has shown promising long-term safety and efficacy in treating refractory rheumatic diseases, including systemic lupus erythematosus, idiopathic inflammatory myositis, and systemic sclerosis.


coremsg

Numerous cases and case series presented at EULAR 2024 add to a rapidly growing collection of evidence that CAR T-cell therapy will be a meaningful option in SLE and other rheumatic diseases.

New Data Support CAR T Cells in Difficult Rheumatic Diseases

promising-long-term-outcomes-with-car-t-cell-therapy-for-refractory-rheumatic-diseases


Promising Long-Term Outcomes with CAR T-Cell Therapy for Refractory Rheumatic Diseases
